Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease

NCT05908695 is registered in ClinicalTrials.gov with Green Valley (Shanghai) Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05908695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05908695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase
Phase 4
Overall status
Recruiting
Start date
August 31, 2023
Completion date
December 31, 2029
Enrollment
1,312 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease